Kagan K O, Hoopmann M, Hammer R, Stressig R, Kozlowski P
Department of Obstetrics and Gynaecology, University of Tuebingen, Tübingen.
Praenatal Medicine and Genetics, praenatal.de, Düsseldorf.
Ultraschall Med. 2015 Feb;36(1):40-6. doi: 10.1055/s-0034-1385059. Epub 2014 Sep 25.
To examine combined first trimester screening (FTS), noninvasive prenatal testing (NIPT) and a two-step policy that combines FTS and NIPT in screening for aneuploidy.
Retrospective study involving 21,052 pregnancies where FTS was performed at the Praxis Praenatal.de in Duesseldorf, Germany. In each case, the sum risk of trisomy 21, 18 and 13 was computed. We assumed that NIPT detects 99 %, 98 %, 90 % and 99 % of cases with trisomy 21, 18, 13 and sex chromosomal abnormalities and that the false-positive rate is 0.5 %. The following screening policies were examined: NIPT or FTS with sum risk cut-offs of 1 in 50 and 1 in 250 in all patients or a two-step-policy with FTS in all patients followed by NIPT in the intermediate sum risk group. For the intermediate risk group, sum risk cut-offs of 1 in 50 and 1 in 1000 and 1 in 150 and 1 in 500 were used.
There were 127, 34, 13 and 15 pregnancies with trisomy 21, 18, 13 and sex chromosomal abnormalities. 23 fetuses had other chromosomal abnormalities with an increased risk for adverse outcome that are not detectable by NIPT. 20,840 pregnancies were classified as normal as ante- and postnatal examinations did not show any signs of clinically significant chromosomal abnormalities. FTS with a sum risk cut-off of 1 in 50 and 1 in 250 detects 81 % and 91 % for all aneuploidies. NIPT detects 88 % of the respective pregnancies. The 2-step approach with sum risk cut-offs of 1 in 50 and 1 in 1000 detects 94 % of all aneuploidies. With sum risk cut-offs of 1 in 150 and 1 in 500, the detection rate is 93 %.
A 2-step policy with FTS for all patients and NIPT in the intermediate risk group results in the highest detection rate of all aneuploidies.
研究孕早期联合筛查(FTS)、无创产前检测(NIPT)以及将FTS和NIPT相结合的两步法在非整倍体筛查中的应用。
对德国杜塞尔多夫Praxis Praenatal.de进行FTS检测的21,052例妊娠进行回顾性研究。在每种情况下,计算21、18和13三体综合征的综合风险。我们假设NIPT能检测出99%、98%、90%和99%的21、18、13三体综合征以及性染色体异常病例,且假阳性率为0.5%。研究了以下筛查策略:对所有患者采用NIPT或FTS,综合风险截断值分别为1/50和1/250;或采用两步法,即对所有患者先进行FTS,然后对综合风险处于中间范围的患者进行NIPT。对于中间风险组,综合风险截断值采用1/50和1/1000以及1/150和1/500。
有127例、34例、13例和15例妊娠分别为21、18、13三体综合征以及性染色体异常。23例胎儿有其他染色体异常,其不良结局风险增加,NIPT无法检测到。20,840例妊娠被分类为正常,因为产前和产后检查均未显示任何具有临床意义的染色体异常迹象。综合风险截断值为1/50和该文档中未提及的另一截断值(原文可能有误)时,FTS能检测出81%和91%的所有非整倍体病例。NIPT能检测出88%的相应妊娠病例。综合风险截断值为1/50和1/1000的两步法能检测出94%的所有非整倍体病例。综合风险截断值为1/150和1/500时,检测率为93%。
对所有患者先进行FTS,然后对中间风险组进行NIPT的两步法能实现所有非整倍体病例的最高检测率。